Sugi Predict

Sugi Predict / Compounds / SCHEMBL51234

SCHEMBL51234

SCHEMBL51234

COC(=O)c1ccc2c(C3CCCCC3)c[nH]c2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.53
▸ ASH1L Q9NR48 1/20 0.46
▸ KIF11 P52732 1/20 0.46
▸ ALDH1A1 P00352 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ ATM Q13315 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ PARP1 P09874 1/20 0.43
▸ NR4A2 P43354 2/20 0.43
▸ GPR84 Q9NQS5 1/20 0.43
▸ APP P05067 2/20 0.42
▸ MTNR1A P48039 1/20 0.42
▸ MTNR1B P49286 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ TRPV1 Q8NER1 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ BRD4 O60885 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ CREBBP Q92793 1/20 0.41
▸ EIF2AK2 P19525 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1173868 0.99 NPC1 (0.54) NPC1ASH1LKIF11ALDH1A1SMN1; SMN2
SCHEMBL8877622 0.89 APP (0.54) NPC1ASH1LKIF11PARP1NR4A2
SCHEMBL2901517 0.86 GABRA1 (0.42) NPC1ALDH1A1APPMTNR1AMTNR1B
SCHEMBL391138 0.84 NPC1 (0.50) NPC1ASH1LKIF11ALDH1A1SMN1; SMN2
SCHEMBL18938495 0.84 NPC1 (0.50) NPC1ASH1LKIF11ALDH1A1PARP1
SCHEMBL391136 0.84 NPC1 (0.50) NPC1ASH1LKIF11ALDH1A1SMN1; SMN2
SCHEMBL391137 0.84 NPC1 (0.50) NPC1ASH1LKIF11ALDH1A1SMN1; SMN2
SCHEMBL1173806 0.84 KMO (0.47) ALDH1A1NPSR1APPKDM4EBRD4
SCHEMBL5349191 0.83 NPC1 (0.49) NPC1ASH1LKIF11ALDH1A1SMN1; SMN2
SCHEMBL393070 0.83 NPC1 (0.49) NPC1ASH1LKIF11ALDH1A1PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220023311-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES INC (US) 2022-01-27 — — US disclosed
US-20220023311-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES INC (US) 2022-01-27 — — US disclosed
US-10987360-B2 Hepatitis B core protein modulators ASSEMBLY BIOSCIENCES, INC. (US) 2021-04-27 — — US disclosed
US-10987360-B2 Hepatitis B core protein modulators ASSEMBLY BIOSCIENCES, INC. (US) 2021-04-27 — — US disclosed
US-20190255067-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES INC (US) 2019-08-22 — — US disclosed
US-20190255067-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES INC (US) 2019-08-22 — — US disclosed
EP-3512845-A1 HEPATITIS B CORE PROTEIN MODULATORS Assembly Biosciences, Inc. (US) 2019-07-24 — — EP disclosed
WO-2018053157-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES, INC. (US) 2018-03-22 — — WO disclosed
WO-2018053157-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES, INC. (US) 2018-03-22 — — WO disclosed
EP-2099804-B1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL MYERS SQUIBB CO (US) 2017-03-22 — — EP disclosed
WO-2005012288-A1 BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE GENELABS TECHNOLOGIES, INC (US) 2005-02-10 — — WO disclosed
CN-1558759-A Viral polymerase inhibitors ���ָ����Ӣ��ķ���ô����޹�˾ 2004-12-29 — — CN disclosed
WO-2004087714-A1 INDOLE ACETAMIDES AS INHIBITORS OF THE HEPATITIS C VIRUS NS5B POLYMERASE ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) 2004-10-14 — — WO disclosed
US-20040171626-A1 Viral polymerase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2004-09-02 — — US disclosed
EP-1414797-A2 HEPATITIS C VIRUS POLYMERASE INHIBITORS WITH A HETEROBICYLIC STRUCTURE BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2004-05-06 — — EP disclosed
EP-1414441-A2 HEPATITIS C VIRUS POLYMERASE INHIBITORS WITH HETEROBICYCLIC STRUCTURE BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2004-05-06 — — EP disclosed
US-20040024190-A1 Viral polymerase inhibitors BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2004-02-05 — — US disclosed
US-20030176433-A1 Viral polymerase inhibitors BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2003-09-18 — — US disclosed
WO-2003010140-A2 HEPATITIS C VIRUS POLYMERASE INHIBITORS WITH HETEROBICYCLIC STRUCTURE BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2003-02-06 — — WO disclosed
WO-2003010141-A2 HEPATITIS C VIRUS POLYMERASE INHIBITORS WITH A HETEROBICYCLIC STRUCTURE BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2003-02-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10987360-B2 Hepatitis B core protein modulators HAVCR2, FABP1, MAVS NPC1 294/4885ASH1L 4022/4885KIF11 4049/4885
US-20030176433-A1 Viral polymerase inhibitors NR4A1, RCOR1, RER1 NPC1 527/4885ASH1L 2164/4885KIF11 3615/4885
US-20190255067-A1 HEPATITIS B CORE PROTEIN MODULATORS HAVCR2, FABP1, MAVS NPC1 294/4885ASH1L 4022/4885KIF11 4049/4885
US-20040171626-A1 Viral polymerase inhibitors POLM, MED1, POLR2H NPC1 889/4885ASH1L 576/4885KIF11 2251/4885
US-20040024190-A1 Viral polymerase inhibitors RCOR1, NR4A1, RER1 NPC1 465/4885ASH1L 2568/4885KIF11 4385/4885
US-20220023311-A1 HEPATITIS B CORE PROTEIN MODULATORS HAVCR2, FABP1, MAVS NPC1 294/4885ASH1L 4022/4885KIF11 4049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.